sclerosis

Sanofi's new multiple sclerosis drug suffered a setback, with its stock price falling more than 4% in pre-market trading.

① Sanofi ① The experimental drug tolebrutinib failed to meet its primary endpoint in a late-stage clinical trial for th...

Stock
2026-01-12
Popular in
  1. Trump explains the cause of his "bruises on the back of his

    Stock
  2. The Fed's "first hawk of the new year": Whether or

    Stock
  3. Will the Fed's rate cut next week be a certainty after the r

    Stock
  4. Storage leaders surge to new highs! Price hike cycle ignites acr

    Stock